These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3926352)

  • 21. Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty.
    Lin TH; LePage ME; Henzl M; Kirkland JL
    J Pediatr; 1986 Dec; 109(6):954-8. PubMed ID: 2946840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone.
    Pescovitz OH; Hench KD; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Sep; 67(3):474-9. PubMed ID: 3137242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue.
    Stanhope R; Pringle PJ; Brook CG
    Acta Paediatr Scand; 1988 Jul; 77(4):525-30. PubMed ID: 3293348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
    Kauli R; Pertzelan A; Ben-Zeev Z; Lewin RP; Kaufman H; Schally AM; Schally AV; Laron Z
    Clin Endocrinol (Oxf); 1984 Apr; 20(4):377-87. PubMed ID: 6232020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome.
    Foster CM; Comite F; Pescovitz OH; Ross JL; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1984 Oct; 59(4):801-5. PubMed ID: 6434582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The significance and characteristics of the LHRH test in diagnosing precocious puberty development in girls: the stimulated LH/FSH quotient differentiates between central precocious puberty and premature thelarche].
    Partsch CJ; Hümmelink R; Lorenzen F; Sippell WG
    Monatsschr Kinderheilkd; 1989 May; 137(5):284-8. PubMed ID: 2525665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.
    Crowley WF; Comite F; Vale W; Rivier J; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1981 Feb; 52(2):370-2. PubMed ID: 6780592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monitoring the treatment of precocious puberty with a GnRH-analog (buserelin): comparison of the GnRH-test with nocturnal pulsatility of LH, testosterone and 17-beta-estradiol].
    Radetti G; Pasquino B; Castellan C; Gentili L; Mengarda G
    Pediatr Med Chir; 1991; 13(5):471-4. PubMed ID: 1788106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cyproterone acetate, LHRH agonist and ovarian surgery in McCune-Albright syndrome with precocious puberty and galactorrhea.
    Carani C; Pacchioni C; Baldini A; Zini D
    J Endocrinol Invest; 1988 Jun; 11(6):419-23. PubMed ID: 2974851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls.
    Houk CP; Kunselman AR; Lee PA
    Pediatrics; 2009 Jun; 123(6):e1059-63. PubMed ID: 19482738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responsivity of pituitary gonadotropes to luteinizing hormone-releasing factor in idiopathic precocious puberty, precocious thelarche, precocious adrenarche, and in patients treated with medroxyprogesterone acetate.
    Reiter EO; Kaplan SL; Conte FA; Grumbach MM
    Pediatr Res; 1975 Feb; 9(2):111-6. PubMed ID: 1090891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
    Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
    J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gonadotrophin and prolactin secretory dynamics in girls with normal puberty, idiopathic precocious puberty and precocious puberty due to hypothalamic hamartoma.
    Uriarte MM; Klein KO; Barnes KM; Pescovitz OH; Loriaux DL; Cutler GB
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):363-8. PubMed ID: 9861328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precocious puberty due to a lipid-cell tumour of the ovary.
    Dengg K; Fink FM; Heitger A; Tabarelli M; Kreczy A; Glatzl J; Berger H
    Eur J Pediatr; 1993 Jan; 152(1):12-4. PubMed ID: 8444198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.